CN105820069A - N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof - Google Patents
N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN105820069A CN105820069A CN201510001109.1A CN201510001109A CN105820069A CN 105820069 A CN105820069 A CN 105820069A CN 201510001109 A CN201510001109 A CN 201510001109A CN 105820069 A CN105820069 A CN 105820069A
- Authority
- CN
- China
- Prior art keywords
- compound
- solvent
- reactions steps
- reaction
- molar ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a new compound. The name of the compound is N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide; molecular weight of the compound is 542.5; and structure of the compound is as shown in the structural formula (compound 1). Meanwhile, the invention provides a preparation method of the compound 1. The compound provided by the invention has good drug-likeness and can be used in the research field of new drugs, especially in the research field of type-II diabetes innovative drugs.
Description
Technical field
The present invention relates to a kind of N-{4-of offer [the bromo-phenyl of 3-(3-)-ureidomethy]-2,5-dibutoxy-phenyl }-Methanesulfomide noval chemical compound, preparation method and the purposes in innovation drug research thereof, this compound molecular weight is little, novel structure, stable in properties, simple in construction, it is adaptable to innovation drug research is developed, and belongs to technical field of chemistry.
Background technology
Carbamide compounds () when being combined with drug target molecule (macromole such as protein, enzyme) active pocket, owing to the hydrogen atom on nitrogen-atoms in urea groups structure is can critical amino acid residues is combined in drug target molecular activity pocket good hydrogen-bond donor, and carbonyl is the good hydrogen bond receptor that critical amino acid residues is combined in drug target molecular activity pocket in its urea groups, therefore in the compound design of innovation drug research, such group is good dominant group.Compound N-and 4-[the bromo-phenyl of 3-(3-)-ureidomethy]-2,5-dibutoxy-phenyl }-Methanesulfomide is the carbamide compounds containing urea groups structure, this compound structure is novel, stable in properties, simple in construction, in the docking research of Computer-Aided Drug Design, find that this compound can have preferably combination with the drug target of some type ii diabetes, there is certain innovation drug research DEVELOPMENT PROSPECT.
Summary of the invention
、A kind of noval chemical compound, it is characterized in that, and the entitled N-{4-of this compound [the bromo-phenyl of 3-(3-)-ureidomethy]-2,5-dibutoxy-phenyl }-Methanesulfomide, the molecular weight of this compound is 542.5, and the structural formula of this compound is shown in following formula: compound 1.
、One prepares noval chemical compound N-{4-[the bromo-phenyl of 3-(3-)-ureidomethy]-2,5-diethoxy-phenyl } method of Methanesulfomide, it is characterized in that, show following the most totally 9 reactions steps of reactions steps a, reactions steps b, reactions steps c, reactions steps d, reactions steps e, reactions steps f, reactions steps g, reactions steps h, reactions steps i including following reaction scheme 1:
The condition of reactions steps a is: brominated alkanes and the molar ratio range 0.8:1 ~ 3:1 of compound A, solvent can be N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, range of reaction temperature 60 ~ 130 degree, in 5 ~ 24 hours response time, reaction is purified to obtain sterling compound B, yield spectra 50% ~ 95% through extraction, crystallization etc. after terminating；The condition of reactions steps b is: nitric acid and compound B molar ratio range 5:1 ~ 1:1, and acetic acid is solvent, 30 minutes to 5 hours response time h, and reaction is purified to obtain product compound C, yield spectra 70% ~ 99% through extraction, crystallization etc. after terminating；The condition of reactions steps c is: N-bromo-succinimide and compound C molar ratio range 0.8:1 ~ 1.3:1), solvent is carbon tetrachloride or dichloromethane, reaction temperature 60 ~ 130 degree, 7 ~ 48 hours response time, reaction is purified to obtain product compound D, yield spectra 70% ~ 99% through extraction, crystallization or silica gel column chromatography etc. after terminating；
The condition of reactions steps d is: potassium phthalimide and compound D molar ratio range are 0.8:1 ~ 1.4:1, solvent is N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, range of reaction temperature 80 ~ 140 degree, in 2 ~ 12 hours response time, reaction is purified to obtain product compound E, yield spectra 65% ~ 99% through extraction, crystallization etc. after terminating；The condition of reactions steps e is: hydrazine hydrate and compound E molar ratio range are 0.8:1 ~ 2.5:1, solvent is single solvent or the combination of solvent of the alcohols solvent in methanol or ethanol or other 5 carbon atoms, range of reaction temperature 40 ~ 120 degree, reaction time range 2 ~ 16 hours, reaction is purified to obtain product compound F, yield spectra 60% ~ 99% through extraction, crystallization etc. after terminating；The condition of reactions steps f is: phenyl chloroformate is 0.8:1 ~ 1.5:1 with the molar ratio range of compound F, triethylamine and compound F molar ratio range are 0.75:1 ~ 2:1, solvent is dichloromethane or N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, range of reaction temperature is 0 ~ 100 degree, 0.5h ~ 24 hour, reaction is purified to obtain product compound G, yield spectra 60% ~ 96% through extraction, crystallization etc. after terminating；The condition of reactions steps g is: m-bromoaniline and compound G molar ratio range are 0.8:1 ~ 1.3:1, triethylamine and compound G mol ratio=0.8:1 ~ 5:1), solvent is N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, reaction temperature is 50 ~ 120 degree, and the response time is 5 ~ 18 hours, reaction is purified to obtain product compound H, yield spectra 50% ~ 90% through concentrate, extract, crystallization etc. after terminating；The condition of reactions steps h is: Nickel dichloride hexahydrate and compound H molar ratio range are 0.9:1 ~ 2.5:1, sodium borohydride and compound H molar ratio range are 0.9:1 ~ 4:1, solvent is dichloromethane or the single solvent such as oxolane or ether or the combination of solvent, response time is 10 minutes ~ 12 hours, reaction is purified to obtain product compound I, yield spectra 50% ~ 95% through extraction, crystallization etc. after terminating；
The condition of reactions steps i is: alkyl sulfonyl chloride and compound I molar ratio range are 0.8:1 ~ 1.5:1, pyridine and compound I molar ratio range are 0.9:1 ~ 1.5:1, solvent is dichloromethane or oxolane or ether or N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, reaction temperature is 0 ~ 80 degree, 3 ~ 18 hours response time, reaction is purified to obtain product compound 1, yield spectra 50% ~ 95% through extraction, crystallization or column chromatography etc. after terminating.
3, the compound that the present invention provides has good quasi-medicated property, can be used for new drug research field and especially treats type ii diabetes field of innovative medicine research.
4, a kind of pharmaceutical composition, including the compound described in the claim 1 of therapeutically effective amount or its pharmaceutically acceptable salt.
5, according to claim 4 requiring compositions, it is characterized in that, this pharmaceutical composition contains one or more pharmaceutically acceptable carrier or excipient further.
6, pharmaceutical composition according to claim 4, is characterized in that, described compound or its pharmaceutically acceptable salt account for gross weight ratio 50% ~ 99.5% as active component.
Below in conjunction with specific embodiment, the present invention is further elaborated, but is not intended to the present invention.
Specific embodiment
Embodiment 1: the structural formula of compound N-{ 4-[the bromo-phenyl of 3-(3-)-ureidomethy]-2,5-dibutoxy-phenyl }-Methanesulfomide (compound 1) is as follows:
The synthetic route of compound N-{ 4-[the bromo-phenyl of 3-(3-)-ureidomethy]-2,5-dibutoxy-phenyl }-Methanesulfomide is as follows:
The concrete preparation method of compound N-{ 4-[the bromo-phenyl of 3-(3-)-ureidomethy]-2,5-dibutoxy-phenyl }-Methanesulfomide is as follows:
The there-necked flask of reactions steps a:250ml adds 125mlN, dinethylformamide, is passed through nitrogen and carries out solvent deoxygenation; it is subsequently adding 2-methyl; Isosorbide-5-Nitrae-hydroquinone (5g, 40.3mmol) and potassium carbonate (16.8g; 121.4mmol); nitrogen is protected, and is heated to 80 DEG C-120 DEG C, is being added dropwise over n-butyl bromide (16.6g; 120.9mmol), reaction is overnight.After reaction terminates, carrying out concentrating under reduced pressure, obtain the solid of brown, add dichloromethane and dissolve, wash 3 times with saturated aqueous common salt, concentrating under reduced pressure i.e. can get crude product Isosorbide-5-Nitrae-dibutoxy-2-methyl-benzene (4.7g, productivity 49.5%)；Reactions steps b: Isosorbide-5-Nitrae-dibutoxy-2-methyl-benzene (4.5g, 19.1mmol) is added in the eggplant type bottle of 250ml, add 100ml acetic acid and make 1,4-dibutoxy-2-methyl-benzene is completely dissolved, and is being added dropwise over nitric acid (4.84ml, 76.3mmol), about 3-5h is reacted under room temperature, after reaction terminates, having yellow solid to separate out, decompression sucking filtration i.e. can get sterling 1,4-dibutoxy-2-methyl-5-nitro-benzene (4.0g, productivity 85.1%)；Reactions steps c: by 1, 4-dibutoxy-2-methyl-5-nitro-benzene (3.5g, 12.5mmol) add the eggplant type bottle of 250ml, join carbon tetrachloride, it is again heated to 60-80 DEG C, add benzoyl peroxide (62.5mg, 0.25mmol) add N-bromo-succinimide (2.2g after 10 minutes, 12.5mmol) reaction 24-48 h, reaction carries out being concentrated under reduced pressure to give the solid of yellow after terminating, add dichloromethane to dissolve, wash three times with saturated aqueous common salt, it is concentrated under reduced pressure to give crude product, separate by column chromatography, petroleum ether is eluant, obtain sterling 1-bromomethyl-2, 5-dibutoxy-4-nitro-benzene (4.2g, 89.4%)；Reactions steps d: by 1-bromomethyl-2,5-dibutoxy-4-nitro-benzene (4g, 11.1mmol) adds in the eggplant type bottle of 250ml, add methanol, be heated to 60-80 DEG C, add potassium phthalimide (2.06g, 11.1mmol) with tetrabutyl ammonium bromide (35.7mg, 0.011mmol), reaction 1h. reaction has white solid to separate out after terminating, and carries out the sucking filtration that reduces pressure, i.e. can get sterling 2-(2,5-dibutoxy-4-Nitro-benzyl)-iso-indoles-1,3-diketone (3.8g, 80.3%)；Reactions steps e: by 2-(2,5-dibutoxy-4-Nitro-benzyl)-iso-indoles-1,3-diketone (3.5g, 8.2mmol) add in the eggplant type bottle of 100ml, add methanol, be heated to 50-80 DEG C, add hydrazine hydrate (0.74g, 11.8mmol) reaction 4-6 h, reaction carries out concentrating under reduced pressure after terminating, add sodium hydroxide solution and the dichloromethane of 3mol/L, obtain organic facies, concentrating under reduced pressure i.e. can get sterling 2,5-dibutoxy-4-Nitro-benzyl amine (2.1g, 86.4%)；Reactions steps f: phenyl chloroformate (1.06g, 6.8mmol) is added in the eggplant type bottle of 100ml, add dichloromethane, add 2,5-dibutoxy-4-Nitro-benzyl amine (2.0g, 6.8mmol) and triethylamine (0.76g, 7.48mmol), reaction 0.5-2 h, reaction is washed 3 times with the hydrochloric acid solution of 10% after terminating, and is concentrated under reduced pressure to give crude product, carries out recrystallization with ethanol and can get sterling (2,5-dibutoxy-4-Nitro-benzyl)-phenyl carbamates (2.8g, productivity 89.3%)；Reactions steps g:(2,5-dibutoxy-4-Nitro-benzyl)-phenyl carbamates (0.5g, 1.18mmol), the bromo-aniline of 3-(202mg, 1.18mmol) with triethylamine (1.19g, 11.8mmol) add in the eggplant type bottle of 100ml, add dioxanes, it is heated to 60-80 DEG C, reaction is overnight, reaction is concentrated under reduced pressure to give crude product after terminating, and carries out recrystallization with methanol, obtains the bromo-phenyl of sterling 1-(3-)-3-(2,5-dibutoxy-4-Nitro-benzyl)-urea (480mg, productivity 82.8%)；nullReactions steps h: by bromo-for 1-(3-phenyl)-3-(2,5-dibutoxy-4-Nitro-benzyl)-urea (350mg,0.71mmol) add in the eggplant type bottle of 100ml，Add methanol，Add Nickel dichloride hexahydrate (290mg，1.22mmol)，After being completely dissolved，Add sodium borohydride (92.5mg，2.44mmol)，Room temperature reaction 5-10 minute，Reaction carries out concentrating under reduced pressure after terminating，Add the hydrochloric acid solution of 10%，Wash three times by ethyl acetate，Obtain aqueous phase，Add ammonia regulation PH > 11，Wash 3 times by ethyl acetate，Obtain organic facies，Concentrating under reduced pressure i.e. can get crude product，Separate by column chromatography，The methylene chloride/methanol of 100:1 is eluant，Obtain sterling 1-(4-amino-2,5-dibutoxy-benzyl) the bromo-phenyl of-3-(3-)-urea (280mg，85.1%)；nullReactions steps i: by 1-(4-amino-2,5-dibutoxy-benzyl) the bromo-phenyl of-3-(3-)-urea (250mg，0.54mmol) add in the eggplant type bottle of 100ml，Add dichloromethane，Add pyridine (46.8mg，0.59mmol)，Carry out nitrogen protection，Add methylsufonyl chloride (61.8mg，0.60mmol)，Room temperature reaction is overnight，After reaction terminates，Hydrochloric acid solution with 10% washs three times，Obtain organic facies，Concentrating under reduced pressure i.e. can get crude product，Separate by column chromatography，The methylene chloride/methanol of 100:1 is eluant，Obtain sterling N-{4-[the bromo-phenyl of 3-(3-)-ureidomethy]-2,5-dibutoxy-phenyl }-Methanesulfomide (130mg，44.5%).1H NMR (400 MHz, DMSO) δ 8.79 (s, 1H), 8.76
(s, 1H), 7.81 (s, 1H), 7.23 – 7.12 (m, 2H), 7.05 (d,J =
7.6 Hz, 1H), 6.94 (s, 1H), 6.87 (s, 1H), 6.44 (t,J = 5.7 Hz, 1H), 4.22
(d,J = 5.7 Hz, 2H), 3.92 (dd,J = 9.1, 4.1 Hz, 4H), 2.92 (s,
3H), 1.74–1.65 (m, 4H), 1.49–1.36 (m, 4H), 0.90 (q,J
= 7.6 Hz, 6H)。
Claims (6)
1. a noval chemical compound, it is characterized in that, and the entitled N-{4-of this compound [the bromo-phenyl of 3-(3-)-ureidomethy]-2,5-dibutoxy-phenyl }-Methanesulfomide (compound 1), the molecular weight of this compound is 542.5, and the structural formula of this compound is shown in following formula: compound 1.
2. prepare noval chemical compound N-{4-[the bromo-phenyl of 3-(3-)-ureidomethy]-2 for one kind, 5-dibutoxy-phenyl } method of-Methanesulfomide, it is characterized in that, show following the most totally 9 reactions steps of reactions steps a, reactions steps b, reactions steps c, reactions steps d, reactions steps e, reactions steps f, reactions steps g, reactions steps h, reactions steps i including following reaction scheme 1:
The condition of reactions steps a is: brominated alkanes and the molar ratio range 1.8:1 ~ 4:1 of compound A, solvent can be N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, range of reaction temperature 60 ~ 130 degree, in 5 ~ 24 hours response time, reaction is purified to obtain sterling compound B, yield spectra 50% ~ 95% through extraction, crystallization etc. after terminating；The condition of reactions steps b is: nitric acid and compound B molar ratio range 5:1 ~ 1:1, and acetic acid is solvent, 30 minutes to 5 hours response time h, and reaction is purified to obtain product compound C, yield spectra 70% ~ 99% through extraction, crystallization etc. after terminating；The condition of reactions steps c is: N-bromo-succinimide and compound C molar ratio range 0.8:1 ~ 1.3:1), solvent is carbon tetrachloride or dichloromethane, reaction temperature 60 ~ 130 degree, 7 ~ 48 hours response time, reaction is purified to obtain product compound D, yield spectra 70% ~ 99% through extraction, crystallization or silica gel column chromatography etc. after terminating；The condition of reactions steps d is: potassium phthalimide and compound D molar ratio range are 0.8:1 ~ 1.4:1, solvent is N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, range of reaction temperature 80 ~ 140 degree, in 2 ~ 12 hours response time, reaction is purified to obtain product compound E, yield spectra 65% ~ 99% through extraction, crystallization etc. after terminating；The condition of reactions steps e is: hydrazine hydrate and compound E molar ratio range are 0.8:1 ~ 2.5:1, solvent is single solvent or the combination of solvent of the alcohols solvent in methanol or ethanol or other 5 carbon atoms, range of reaction temperature 40 ~ 120 degree, reaction time range 2 ~ 16 hours, reaction is purified to obtain product compound F, yield spectra 60% ~ 99% through extraction, crystallization etc. after terminating；The condition of reactions steps f is: phenyl chloroformate is 0.8:1 ~ 1.5:1 with the molar ratio range of compound F, triethylamine and compound F molar ratio range are 0.75:1 ~ 2:1, solvent is dichloromethane or N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, range of reaction temperature is 0 ~ 100 degree, 0.5h ~ 24 hour, reaction is purified to obtain product compound G, yield spectra 60% ~ 96% through extraction, crystallization etc. after terminating；The condition of reactions steps g is: m-bromoaniline and compound G molar ratio range are 0.8:1 ~ 1.3:1, triethylamine and compound G mol ratio=0.8:1 ~ 5:1), solvent is N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, reaction temperature is 50 ~ 120 degree, and the response time is 5 ~ 18 hours, reaction is purified to obtain product compound H, yield spectra 50% ~ 90% through concentrate, extract, crystallization etc. after terminating；The condition of reactions steps h is: Nickel dichloride hexahydrate and compound H molar ratio range are 0.9:1 ~ 2.5:1, sodium borohydride and compound H molar ratio range are 0.9:1 ~ 4:1, solvent is dichloromethane or the single solvent such as oxolane or ether or the combination of solvent, response time is 10 minutes ~ 12 hours, reaction is purified to obtain product compound I, yield spectra 50% ~ 95% through extraction, crystallization etc. after terminating；The condition of reactions steps i is: alkyl sulfonyl chloride and compound I molar ratio range are 0.8:1 ~ 1.5:1, pyridine and compound I molar ratio range are 0.9:1 ~ 1.5:1, solvent is dichloromethane or oxolane or ether or N, N dimethylformamide or dimethyl sulfoxide or acetone or 1, single solvent or the combinations of solvent such as 4 dioxane, reaction temperature is 0 ~ 80 degree, 3 ~ 18 hours response time, reaction is purified to obtain product compound 1, yield spectra 50% ~ 95% through extraction, crystallization, column chromatography etc. after terminating.
3. the compound that the present invention provides has good quasi-medicated property, can be used for new drug research field and especially treats type ii diabetes field of innovative medicine research.
4. a pharmaceutical composition, including the compound described in the claim 1 of therapeutically effective amount or its pharmaceutically acceptable salt.
Pharmaceutical composition the most according to claim 4, is characterized in that, this pharmaceutical composition contains one or more pharmaceutically acceptable carrier or excipient further.
Pharmaceutical composition the most according to claim 4, is characterized in that, described compound or its pharmaceutically acceptable salt account for gross weight ratio 50% ~ 99.5% as active component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510001109.1A CN105820069A (en) | 2015-01-05 | 2015-01-05 | N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510001109.1A CN105820069A (en) | 2015-01-05 | 2015-01-05 | N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105820069A true CN105820069A (en) | 2016-08-03 |
Family
ID=56986750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510001109.1A Pending CN105820069A (en) | 2015-01-05 | 2015-01-05 | N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105820069A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106167456A (en) * | 2015-05-20 | 2016-11-30 | 齐鲁工业大学 | New Type Urea albuminoid tyrosine-phosphatase 1B inhibitor and preparation method thereof, pharmaceutical composition and purposes |
| CN106491577A (en) * | 2016-09-28 | 2017-03-15 | 齐鲁工业大学 | A kind of new two butoxyphenyls methylsulfonyl amine adjusts the compound and its medical usage of estrogen-related receptor activity |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418191A (en) * | 2000-08-21 | 2003-05-14 | 株式会社太平洋 | Novel thiourea derivatives and the pharmaceutical compositions containing thd same |
| US20040259912A1 (en) * | 2001-09-28 | 2004-12-23 | Takahiro Matsumoto | Benzine derivatives, process for preparing the same and use thereof |
| CN1852891A (en) * | 2003-07-02 | 2006-10-25 | 格吕伦塔尔有限公司 | Cn1852891 |
| CN101142174A (en) * | 2005-03-19 | 2008-03-12 | 株式会社Amorepacific | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist, and pharmaceutical compositions containing the same |
| CN101516361A (en) * | 2006-09-28 | 2009-08-26 | 亚瑞特医疗公司 | Soluble epoxide hydrolase inhibitors |
| WO2010146236A1 (en) * | 2009-06-16 | 2010-12-23 | Biotie Therapies Corp. | Urea substituted sulphonamide derivatives |
-
2015
- 2015-01-05 CN CN201510001109.1A patent/CN105820069A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418191A (en) * | 2000-08-21 | 2003-05-14 | 株式会社太平洋 | Novel thiourea derivatives and the pharmaceutical compositions containing thd same |
| US20040259912A1 (en) * | 2001-09-28 | 2004-12-23 | Takahiro Matsumoto | Benzine derivatives, process for preparing the same and use thereof |
| CN1852891A (en) * | 2003-07-02 | 2006-10-25 | 格吕伦塔尔有限公司 | Cn1852891 |
| CN101142174A (en) * | 2005-03-19 | 2008-03-12 | 株式会社Amorepacific | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist, and pharmaceutical compositions containing the same |
| CN101163670A (en) * | 2005-03-19 | 2008-04-16 | 株式会社太平洋 | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist, and pharmaceutical compositions containing the same |
| CN101516361A (en) * | 2006-09-28 | 2009-08-26 | 亚瑞特医疗公司 | Soluble epoxide hydrolase inhibitors |
| WO2010146236A1 (en) * | 2009-06-16 | 2010-12-23 | Biotie Therapies Corp. | Urea substituted sulphonamide derivatives |
Non-Patent Citations (4)
| Title |
|---|
| CAO RUIKAIET AL.: ""Oligoamide Duplexes as Organogelators"", 《ORGANIC LETTERS》 * |
| MASAKI TAKAHASHI等: ""A new approach toward light-harvesting reverse micelles from donor–acceptor miscible blends"", 《TETRAHEDRON》 * |
| TANG YING等: ""Diiron Complexes with Pendant Phenol Group(s) as Mimics of the Diiron Subunit of [FeFe]-Hydrogenase: Synthesis, Characterisation, and Electrochemical Investigation"", 《EUR. J. INORG. CHEM.》 * |
| WANG GUI-TAO等: ""Hydrogen bonded arylamide-link ed chole steryl dimeso genic liquid crystals: a study of the length and side chain effects"", 《TETRAHEDRON》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106167456A (en) * | 2015-05-20 | 2016-11-30 | 齐鲁工业大学 | New Type Urea albuminoid tyrosine-phosphatase 1B inhibitor and preparation method thereof, pharmaceutical composition and purposes |
| CN106491577A (en) * | 2016-09-28 | 2017-03-15 | 齐鲁工业大学 | A kind of new two butoxyphenyls methylsulfonyl amine adjusts the compound and its medical usage of estrogen-related receptor activity |
| CN106491577B (en) * | 2016-09-28 | 2020-02-18 | 齐鲁工业大学 | Compound for regulating estrogen related receptor activity by dibutoxyphenyl-methanesulfonamide and medical application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2604608E (en) | Method for producing methyl- {4,6-diamino-2-[1-(2-fluorobenzyl) -1h-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-5-yl}-methyl carbamate and its purification for its use as a pharmaceutical agent | |
| CN105481922B (en) | Preparation method of cangrelor intermediate | |
| TW201118098A (en) | Processes for preparing pemetrexed | |
| TWI359135B (en) | Organic compounds | |
| CN105820069A (en) | N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dibutoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| CN105820068A (en) | N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dipropoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| CN105820094A (en) | 4-methoxy-benzyl-based substituted benzamide new compound, preparation method and application | |
| CN105820093A (en) | N-benzyl-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethyoxyl benzamide new compound and preparation method and application thereof | |
| CN105820067A (en) | N-{[2,5-diethoxy-4-[(3-phenyl-ureido)-methyl]-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| ES2758677T3 (en) | Procedure for the preparation of indanamine derivatives and new synthetic intermediates | |
| CN105820071A (en) | N-{4-[3-(4-bromo-phenyl)-ureidomethyl]-2,5-diethoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| CN105820085A (en) | Ethanesulfonic acid{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-diethoxy-phenyl}-amide new compound, preparation method and application | |
| CN105837476A (en) | Novel N-{4-[3-(3-bromo-phenyl)-carbamido methyl]-2,5-diethoxy-phenyl}-methanesulfonamide compound, preparation method and application | |
| CN105820083A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-phenyl-benzamide new compound and preparation method and application thereof | |
| CN105820082A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-isopropyl-benzamide new compound and preparation method and application thereof | |
| CN105820090A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-(3-methoxy-phenyl)-benzamide new compound and preparation method and application thereof | |
| CN105820078A (en) | 2-benzyloxy-5-[3-(2,5-diethoxy-4-methanesulfonyl-benzyl)-ureido]- methyl benzoate new compound and preparation method and application thereof | |
| CN105820070A (en) | N-{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-dimethoxy-phenyl}-methanesulfonamide new compound, new intermediate, preparation method and application | |
| CN105820087A (en) | 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-p-methylphenyl-benzamide new compound and preparation method and application thereof | |
| CN105820077A (en) | 2-butoxyl-5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-methyl benzoate new compound and preparation method and application thereof | |
| CN105820073A (en) | N-{[2,5-diethoxy-4-[(3-phenyl-ureido)-methyl]-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| CN105820072A (en) | N-{[2,5-diethoxy-4-[3-(4-methoxy-phenyl)-ureidomethyl]-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| CN105820075A (en) | N-{4-[3-(3,4-dimethoxy-phenyl)-ureidomethyl]-2,5-diethoxy-phenyl}-methanesulfonamide new compound and preparation method and application thereof | |
| CN105820139A (en) | 3-(pyrrolidine-1-carbonyl)-phenyl-based substituted methanesulfonamide new compound and preparation and application | |
| CN105820076A (en) | N-[2,5-diethoxy-4-(3-p-tolyl-ureidomethyl)-phenyl]-methanesulfonamide new compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160803 |